Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Stereotaxis Inc. (STXS : AMEX)

• Company Description    Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to allow physicians to navigate catheters, guidewires and stent delivery devices through the blood vessels and chambers of the heart to treatment sites. Number of Employees: 139

• Price / Volume Information    Yesterday's Closing Price: $1.82 Daily Weekly Monthly 20 Day Moving Average: 448,263 shares Shares Outstanding: 97.25 (millions) Market Capitalization: $176.99 (millions) Beta: 1.38 52 Week High: $3.59 52 Week Low: $1.54 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -12.50% -9.12% 12 Week -25.10% -21.41% Year To Date -20.87% -18.01%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 710 North Tucker Boulevard Suite 110 - ST.LOUIS,MO 63101 USA ph: 314-678-6100 fax: 314-678-6159 investors@stereotaxis.com http://www.stereotaxis.com

• General Corporate Information    Officers David L. Fischel - Chairman and Chief Executive Officer Kimberly R. Peery - Chief Financial Officer David W. Benfer - Director Nathan Fischel - Director Arun Menawat - Director Peer Information Stereotaxis Inc. (ABMD) Stereotaxis Inc. (DMDS) Stereotaxis Inc. (CPWY.) Stereotaxis Inc. (EQUR) Stereotaxis Inc. (ECIA) Stereotaxis Inc. (FMS) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 85916J409 SIC: 3845 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/11/26 Share - Related Items Shares Outstanding: 97.25 Most Recent Split Date: 7.00 (0.10:1) Beta: 1.38 Market Capitalization: $176.99 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.05 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.18 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 12.60 Price/Cash Flow: - Price / Sales: 5.47 EPS Growth vs. Year Ago Period: 33.33% vs. Previous Quarter: -100.00% Sales Growth vs. Year Ago Period: 36.31% vs. Previous Quarter: 15.78% ROE 12/31/25 - -291.99 09/30/25 - -469.10 06/30/25 - -440.00 ROA 12/31/25 - -38.07 09/30/25 - -43.67 06/30/25 - -50.62 Current Ratio 12/31/25 - 1.51 09/30/25 - 1.31 06/30/25 - 1.06 Quick Ratio 12/31/25 - 1.09 09/30/25 - 0.81 06/30/25 - 0.59 Operating Margin 12/31/25 - -54.30 09/30/25 - -65.05 06/30/25 - -73.43 Net Margin 12/31/25 - -66.85 09/30/25 - -78.56 06/30/25 - -73.43 Pre-Tax Margin 12/31/25 - -66.85 09/30/25 - -78.56 06/30/25 - -73.43 Book Value 12/31/25 - 0.14 09/30/25 - 0.07 06/30/25 - 0.02 Inventory Turnover 12/31/25 - 1.56 09/30/25 - 1.49 06/30/25 - 1.72 Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©